JS001 (toripalimab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JS001 (toripalimab), covering 2024-09-19 to 2024-09-19. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [Phase 3]